Relaying what matters next.

The Air Force’s first Collaborative Combat Aircraft are moving from hangars to the sky. Here is how first flights reshape tactics and force design, what industry must scale, and which tests and policies unlock FY26 production.

In 2025, the first human data for in vivo PCSK9 base editing showed large, durable LDL-C drops after a single infusion. If safety holds and access follows, one-and-done edits could shift heart disease prevention from chronic care to permanent risk cut.

In March 2025, Firefly’s Blue Ghost stuck a clean touchdown at Mare Crisium, while Intuitive Machines’ IM-2 tipped over inside a south polar crater. What those back-to-back outcomes reveal about landing at the Moon’s edge.

The SEC’s October 2025 window for multiple Solana spot ETFs is the next big catalyst for crypto market structure. Here is how approve, deny, or conditional outcomes could ripple across flows, staking, DeFi, and the path for other altcoin ETFs.

Google is putting Gemini inside Chrome with AI Mode in the address bar, cross‑tab reasoning, and upcoming on‑page task automation. Here is what it means for SEO, ecommerce, privacy, and how to make your site agent‑readable now.

Workday’s Sana deal and new Agent System of Record mark a shift from scattered copilots to managed fleets of interoperable agents. Here is how governance, open protocols, and a data moat could reset enterprise AI middleware.

The U.S. Army’s Typhon launchers just appeared in Japan, putting Tomahawk and SM-6 back on land along the First Island Chain. Here is how the system’s loadout, kill-chain integration, mobility, and escalation risks reshape Indo-Pacific deterrence—and why Europe is next.

The DOE’s new Speed to Power push and Microsoft’s fresh Wisconsin build signal a scramble to keep firm capacity online as data centers surge. Here is how rules, costs, and resources are shifting from 2026 to 2030—and who wins or pays.

Retro Biosciences is set to begin first human testing in Australia of RTR242, an autophagy-activating pill aimed at Alzheimer’s. Paired with OpenAI’s GPT‑4b micro reprogramming work, it is a pivotal test for geroscience in the clinic.

China has launched Tianwen‑2 to Kamoʻoalewa, a tiny companion of Earth that might be a fragment of the Moon. The mission will try touch‑and‑go and anchoring‑drill sampling, with a target return in 2027 and big stakes for planetary defense.

A peer reviewed Nature study of Jezero’s Bright Angel rocks elevates Perseverance’s best hint of Martian life. We decode what a potential biosignature really means, the mineral organic clues the rover found, and why a leaner sample return must move faster.

The SEC’s Sept 17 approval of generic listing standards for commodity-based ETPs, paired with July 29 in-kind creation and redemption orders, cleared the path for Cboe to list REX‑Osprey’s Dogecoin and XRP ETFs on Sept 18. Here is what changes next.

Google’s September rollout of Gemini inside Chrome is the moment agentic browsing jumps from demo to default. Here is what tab‑aware synthesis and upcoming multi‑step, cursor‑driven automation mean for search, ecommerce, privacy, extensions, and your roadmap.

Israel says its 100 kilowatt class Iron Beam will be ready for operational use later in 2025. If lasers really cut interception costs to a few dollars, the economics of barrages and drone swarms change fast. Here is how and where it still breaks.

Australia just moved Ghost Shark from prototype to fleet, committing A$1.7 billion to field dozens of extra‑large autonomous subs within five years. The decision signals a pivot from slow, crewed AUKUS timelines to scalable undersea autonomy.

Washington’s new Speed to Power push aims to deliver the electricity surge needed for AI and data centers by fast-tracking generation and transmission. Here is how it works, who benefits, who pays, and what it means for prices and emissions.

Retro Biosciences will dose its first Alzheimer’s patients in Australia with RTR242, an autophagy-boosting pill. The study is a test case for proving longevity mechanisms through disease endpoints, and for a new path in regulation and funding.

In 2025 the FDA gave Loyal’s canine longevity pill a reasonable expectation of effectiveness, opening the first practical regulatory path for lifespan extension. Here is how the dog route could speed safe human geroprotectors.